Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.58 |
| ▸ | PGK1 | P00558 | 3/20 | 0.53 |
| ▸ | PGK2 | P07205 | 3/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21993641 | 1.00 | ACP3 (0.58) | ACP3PGK1PGK2ABCC4LMNA | |
| SCHEMBL9407120 | 0.91 | PGK1 (0.59) | ACP3PGK1PGK2PTPN5 | |
| SCHEMBL24372954 | 0.89 | ACP3 (0.49) | ACP3PGK1PGK2ABCC4LMNA | |
| SCHEMBL24372888 | 0.87 | ACP3 (0.46) | ACP3PGK1PGK2PTPN5 | |
| Benzylphosphonic Acid SCHEMBL44318 | 0.86 | HPGD (0.60) | ACP3PGK1PGK2TSHR | |
| Benzylphosphonic Acid SCHEMBL11474641 | 0.84 | HPGD (0.58) | ACP3PGK1PGK2TSHR | |
| Benzylphosphonic Acid SCHEMBL915222 | 0.84 | HPGD (0.58) | ACP3PGK1PGK2TSHR | |
| Benzylphosphonic Acid SCHEMBL5332218 | 0.84 | HPGD (0.58) | ACP3PGK1PGK2TSHR | |
| Benzylphosphonic Acid SCHEMBL11339355 | 0.84 | HPGD (0.58) | ACP3PGK1PGK2TSHR | |
| Benzylphosphonic Acid SCHEMBL9182484 | 0.84 | HPGD (0.58) | ACP3PGK1PGK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935129-B1 | LIGANDS FOR NANO-SIZED MATERIALS | MERCK PATENT GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-20220127286-A1 | LIGANDS FOR NANO-SIZED MATERIALS | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-9902712-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| EP-3083584-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-08 | — | — | US | disclosed |
| CN-101208371-B | Method for preparing polyester and polyester manufactured by the method as well as polyester formed body | TOYO BOSEKI | 2011-08-10 | — | — | CN | disclosed |
| US-7868126-B2 | Process for producing polyester, polyester produced using said process, and polyester molded product | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-1842868-B1 | PROCESS FOR PRODUCING POLYESTER, POLYESTER PRODUCED USING SAID PROCESS, AND POLYESTER MOLDED PRODUCT | TOYO BOSEKI (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20090082529-A1 | Polyester, Process for Producing Polyester, and Polyester Molded Article | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080249280-A1 | Process for Producing Polyester, Polyester Produced Using Said Process, and Polyester Molded Product | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-10-09 | — | — | US | disclosed |
| WO-1998054702-A1 | MAGNETIC RECORDING MEDIA INCORPORATING SURFACE TREATED MAGNETIC PIGMENT | IMATION CORP. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5612352-A | INHIBITORS OF SQUALENE SYNTHASE AND ANTICHOLESTEROL AGENTS WITH BIPHENYLQUINUCLIDINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-03-18 | — | — | US | disclosed |
| EP-0625979-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-30 | — | — | EP | disclosed |
| EP-0526488-B1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS | PFIZER (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5326905-A | Benzylphosphonic acid tyrosine kinase inhibitors | PFIZER INC. (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0596058-A1 | BIPHENYLYLQUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993021184-A1 | BIPHENYLYLQUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993015073-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0526488-A1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS. | PFIZER (US) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991015495-A1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127286-A1 | LIGANDS FOR NANO-SIZED MATERIALS | L1CAM, EPCAM, SELPLG | ACP3 1449/4885PGK1 4418/4885PGK2 4551/4885 |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | TNNC1, IAPP, TNNI3 | ACP3 395/4885PGK1 2004/4885PGK2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.